Antoñanzas F - Search Results

1

Epidemiology of MRSA CC398 in hospitals located in Spanish regions with different pig-farming densities: a multicentre study.

Ceballos S, Aspiroz C, Ruiz-Ripa L, Reynaga E, Azcona-Gutiérrez JM, Rezusta A, Seral C, Antoñanzas F, Torres L, López C, López-Cerero L, Cercenado E, Zarazaga M, Torres C; Study Group of clinical LA-MRSA. Ceballos S, et al. Among authors: antonanzas f. J Antimicrob Chemother. 2019 Aug 1;74(8):2157-2161. doi: 10.1093/jac/dkz180. J Antimicrob Chemother. 2019. PMID: 31098612

2

Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus.

Antonanzas F, Lozano C, Torres C. Antonanzas F, et al. Pharmacoeconomics. 2015 Apr;33(4):285-325. doi: 10.1007/s40273-014-0242-y. Pharmacoeconomics. 2015. PMID: 25447195 Review.

3

Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model.

Pradas R, Gil de Miguel A, Álvaro A, Gil-Prieto R, Lorente R, Méndez C, Guijarro P, Antoñanzas F. Pradas R, et al. Among authors: antonanzas f. BMC Infect Dis. 2013 Apr 11;13:175. doi: 10.1186/1471-2334-13-175. BMC Infect Dis. 2013. PMID: 23578307 Free PMC article.

4

[Health care resources utilization in HIV-infected patients: creation of a data base and cost results].

Mompó C, Abbas I, Santín M, Rovira J, Antón F, Tomás C, Antoñanzas F. Mompó C, et al. Among authors: antonanzas f. Gac Sanit. 2000 Jan-Feb;14(1):39-47. doi: 10.1016/s0213-9111(00)71427-0. Gac Sanit. 2000. PMID: 10757861 Free article. Spanish.

5

Policies to Reduce Antibiotic Consumption: The Impact in the Basque Country.

Rojas P, Antoñanzas F. Rojas P, et al. Among authors: antonanzas f. Antibiotics (Basel). 2020 Jul 19;9(7):423. doi: 10.3390/antibiotics9070423. Antibiotics (Basel). 2020. PMID: 32707701 Free PMC article.

6

Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain.

Antoñanzas F, Garuz R, Rovira J, Antón F, Trinxet C, Navas E, Salleras L. Antoñanzas F, et al. Pharmacoeconomics. 1995 May;7(5):428-43. doi: 10.2165/00019053-199507050-00007. Pharmacoeconomics. 1995. PMID: 10155330

7

Defining and Measuring the Affordability of New Medicines: A Systematic Review.

Antoñanzas F, Terkola R, Overton PM, Shalet N, Postma M. Antoñanzas F, et al. Pharmacoeconomics. 2017 Aug;35(8):777-791. doi: 10.1007/s40273-017-0514-4. Pharmacoeconomics. 2017. PMID: 28477220 Review.

8

The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.

Antonanzas F, Juárez-Castelló C, Lorente R, Rodríguez-Ibeas R. Antonanzas F, et al. Pharmacoeconomics. 2019 Dec;37(12):1469-1483. doi: 10.1007/s40273-019-00838-w. Pharmacoeconomics. 2019. PMID: 31535280

9

Economic evaluations in the EURONHEED: a comparative analysis.

Hutter F, Antoñanzas F. Hutter F, et al. Among authors: antonanzas f. Pharmacoeconomics. 2009;27(7):561-70. doi: 10.2165/11310060-000000000-00000. Pharmacoeconomics. 2009. PMID: 19663527 Review.

10

The Value of Medicines: A Crucial but Vague Concept.

Antoñanzas F, Terkola R, Postma M. Antoñanzas F, et al. Pharmacoeconomics. 2016 Dec;34(12):1227-1239. doi: 10.1007/s40273-016-0434-8. Pharmacoeconomics. 2016. PMID: 27444306 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters